Although HER2 amplification is a common event that is seen in 15–20% of invasive breast cancers, it has been challenging to capture the biology at the stage that HER2 amplification occurs in pre-invasive breast neoplasia. This evidence concerns the gene ERBB2 and breast carcinoma.